Membrane-type-1 matrix metalloproteinase, matrix metalloproteinase 2, and tissue inhibitor of matrix proteinase 2 in prostate cancer: identification of patients with poor prognosis by immunohistochemistry
Authors:
- Dominique TrudelDominique Trudel
- Yves FradetYFYves Fradet
- François MeyerFMFrançois Meyer
- François HarelFHFrançois Harel
- Bernard TêtuBTBernard Têtu
- 1 May 2008
- journal article
- Published by Elsevier in Human Pathology
- Vol. 39 (5) , 731-739
Abstract
No abstract availableKeywords
This publication has 25 references indexed in Scilit:
- Matrix metalloproteinase inhibitors for cancer therapy: the current situation and future prospectsExpert Opinion on Therapeutic Targets, 2003
- Prognostic Significance of Matrix Metalloproteinase 2 and Tissue Inhibitor of Metalloproteinase 2 Expression in Prostate CancerLaboratory Investigation, 2003
- New functions for the matrix metalloproteinases in cancer progressionNature Reviews Cancer, 2002
- New Functions of Stromal Proteases and Their Inhibitors in Tumor ProgressionSurgical Oncology Clinics of North America, 2001
- International trends and patterns of prostate cancer incidence and mortalityInternational Journal of Cancer, 2000
- In situ hybridization studies of metalloproteinases 2 and 9 and TIMP-1 and TIMP-2 expression in human prostate cancerClinical & Experimental Metastasis, 1997
- Effect of Neoadjuvant Endocrine Therapy (Combined Androgen Blockade) on Normal Prostate and Prostatic CarcinomaAmerican Journal of Surgical Pathology, 1996
- Mechanism Of Cell Surface Activation Of 72-kDa Type IV CollagenaseJournal of Biological Chemistry, 1995
- The TNM classification of prostate cancerThe Prostate, 1992
- Use of avidin-biotin-peroxidase complex (ABC) in immunoperoxidase techniques: a comparison between ABC and unlabeled antibody (PAP) procedures.Journal of Histochemistry & Cytochemistry, 1981